NCT07634562 TLI- and ATG-Enabled Minimization Protocol in Liver Transplantation
| NCT ID | NCT07634562 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Stanford University |
| Condition | Liver Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 12 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2031-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 12 participants in total. It began in 2026-09-01 with a primary completion date of 2031-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The unmet medical need in solid organ transplantation is to eliminate the lifelong requirement of powerful immune suppression drug combinations with their attendant side effects, and to prevent immune mediated rejection of the organ transplant. The proposed trial is designed to study if following a 'standard of care' deceased donor liver transplant host conditioning using Total Lymphoid Irradiation (TLI) and Anti-Tthymocyte Globulin (ATG) will result in operational tolerance and ultimately allow for immunosuppression drug minimization or cessation. It has been hypothesized that the ATG and TLI conditioning regimen post liver transplant will be safe and well tolerated and will result in recipients successfully being withdrawn from immunosuppression within 2 years after liver transplantation. We will test the hypothesis that by using a conditioning regimen of ATG and TLI to induce this operational tolerance will allow immunosuppressive drug minimization and cessation while maintaining normal graft function and without the risk of graft rejection. Importance of this knowledge: Operational tolerance occurs spontaneously in a minority of liver transplant recipients; however, predictable and reproducible induction of tolerance remains an unmet need. Building on extensive experience with TLI-based tolerance induction in kidney transplantation at Stanford, this study aims to evaluate whether a non-myeloablative conditioning regimen using TLI and ATG can safely facilitate immunosuppression minimization and withdrawal in liver transplant recipients without the use of donor hematopoietic cell infusion.
Eligibility Criteria
Inclusion Criteria: * Undergoing liver transplantation at Stanford University * No contraindications to Total Lymphoid Irradiation or rabbit antithymocyte globulin (rATG) Exclusion Criteria: * Contraindications to Total Lymphoid Irradiation (e.g. pregnancy, bone marrow suppression or disease, autoimmune disease, prior radiation in the field) * Contraindications to rATG * Patients with history of hepatocellular carcinoma (HCC) or other malignancies with exception of non melanoma skin cancer in remission * Model of End-Stage Liver Disease (MELD) score \> 25 * Liver transplants with severe reperfusion syndrome (hemodynamic instability requiring 3 or more pressors after reperfusion) * Liver transplant with early allograft dysfunction (Orloff criteria) * Diagnosis of hepatitis B * Diagnosis of hepatitis C, except for patients that have been treated and eradicated of hepatitis C * Virtual and/or flow crossmatch positive (MFI added up to 8000 for each DSA with MFI\>1000). * Subject has previously received or is receiving another organ for transplant other than liver * Subject is currently on dialysis * Recipient or donor is HIV positive * Subject has received an ABO incompatible donor * Subject has received a donor liver greater than 65 years of age * Subject has an active infection at the time of transplant * Subject will require immunosuppressive agent other than those prescribed in this study * Subject is pregnant or lactating * Subject is unlikely to comply with the visits scheduled in the protocol, including protocol biopsies * Subject has any form of current substance use, psychiatric disorder or condition that may invalidate communication with the Investigators
Contact & Investigator
Stephan Busque, MD, MSc
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT07634562 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Liver Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07634562 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07634562 currently recruiting?
Yes, NCT07634562 is actively recruiting participants. Visit ClinicalTrials.gov or contact Stanford University to inquire about joining.
Where is the NCT07634562 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT07634562 clinical trial?
NCT07634562 is sponsored by Stanford University. The principal investigator is Stephan Busque, MD, MSc at Stanford University. The trial plans to enroll 12 participants.